Treatment with ruxolitinib cream resulted in significant disease control over 52 weeks in a subset of children with moderate/more extensive atopic dermatitis (AD) in a randomized trial that evaluated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results